Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.48 |
| ▸ | PLK1 | P53350 | 6/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | SMO | Q99835 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932332 | 0.88 | ACHE (0.49) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL9932871 | 0.88 | KDR (0.48) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL9931983 | 0.83 | KMT2A (0.46) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL9931706 | 0.81 | SMO (0.63) | SMOHCAR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL9932994 | 0.80 | MEN1 (0.46) | SMOKMT2AMEN1CYP3A4ALDH1A1 | |
| SCHEMBL9932137 | 0.80 | LMNA (0.51) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL9932662 | 0.77 | ITGB2 (0.44) | SMOKMT2AMEN1CYP3A4ALDH1A1 | |
| SCHEMBL9932108 | 0.76 | SMO (0.63) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL9932562 | 0.74 | SMO (0.49) | SMOKMT2AMEN1CYP3A4ALDH1A1 | |
| SCHEMBL9932229 | 0.74 | SMO (0.61) | SMOKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | KDR 1623/4885PTK2 3203/4885PLK1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.